JP2020500015A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500015A5
JP2020500015A5 JP2019522553A JP2019522553A JP2020500015A5 JP 2020500015 A5 JP2020500015 A5 JP 2020500015A5 JP 2019522553 A JP2019522553 A JP 2019522553A JP 2019522553 A JP2019522553 A JP 2019522553A JP 2020500015 A5 JP2020500015 A5 JP 2020500015A5
Authority
JP
Japan
Prior art keywords
polypeptide
domain
mhc class
heterodimer
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/001508 external-priority patent/WO2018087597A1/en
Publication of JP2020500015A publication Critical patent/JP2020500015A/ja
Publication of JP2020500015A5 publication Critical patent/JP2020500015A5/ja
Pending legal-status Critical Current

Links

JP2019522553A 2016-11-09 2017-11-08 組換えpMHCクラスII分子 Pending JP2020500015A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419947P 2016-11-09 2016-11-09
US62/419,947 2016-11-09
PCT/IB2017/001508 WO2018087597A1 (en) 2016-11-09 2017-11-08 Recombinant pmhc class ii molecules

Publications (2)

Publication Number Publication Date
JP2020500015A JP2020500015A (ja) 2020-01-09
JP2020500015A5 true JP2020500015A5 (cg-RX-API-DMAC7.html) 2020-12-17

Family

ID=62065064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522553A Pending JP2020500015A (ja) 2016-11-09 2017-11-08 組換えpMHCクラスII分子

Country Status (16)

Country Link
US (2) US20180127481A1 (cg-RX-API-DMAC7.html)
EP (2) EP4613336A3 (cg-RX-API-DMAC7.html)
JP (1) JP2020500015A (cg-RX-API-DMAC7.html)
KR (1) KR102646495B1 (cg-RX-API-DMAC7.html)
CN (1) CN110291111A (cg-RX-API-DMAC7.html)
AU (2) AU2017357865B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019009477A2 (cg-RX-API-DMAC7.html)
CA (1) CA3042615A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019004751A2 (cg-RX-API-DMAC7.html)
DK (1) DK3538559T3 (cg-RX-API-DMAC7.html)
ES (1) ES3035837T3 (cg-RX-API-DMAC7.html)
IL (1) IL266391A (cg-RX-API-DMAC7.html)
MX (1) MX2019005497A (cg-RX-API-DMAC7.html)
NZ (1) NZ753596A (cg-RX-API-DMAC7.html)
SG (1) SG10201913956RA (cg-RX-API-DMAC7.html)
WO (1) WO2018087597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CN105899229A (zh) 2013-11-04 2016-08-24 Uti有限合伙公司 用于持续的免疫治疗的方法和组合物
WO2016198932A2 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
WO2018119114A1 (en) 2016-12-22 2018-06-28 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
CN111741746A (zh) 2017-11-29 2020-10-02 乌第有限合伙公司 治疗自身免疫性疾病的方法
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
CA3114446A1 (en) 2018-10-05 2020-04-09 Oregon Health & Science University Recombinant polypeptides comprising modified mhc class ii dr.alpha.1 domains and methods of use
WO2020181062A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2020181273A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
JP7691927B2 (ja) * 2019-03-06 2025-06-12 キュー バイオファーマ, インコーポレイテッド T細胞調節抗原提示ポリペプチド及びその使用方法
KR20220044683A (ko) * 2019-08-09 2022-04-11 프라운호퍼 게젤샤프트 쭈르 푀르데룽 데어 안겐반텐 포르슝 에. 베. 관절염 치료를 위한 hla-dr/cii 펩티드 복합체
WO2021035049A1 (en) * 2019-08-21 2021-02-25 Uti Limited Partnership Improved recombinant pmhc molecules
JP7726881B2 (ja) * 2019-12-02 2025-08-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ペプチド-mhc iiタンパク質構築物およびそれらの使用
AU2021272895A1 (en) 2020-05-12 2022-09-22 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
CN111808170A (zh) * 2020-06-29 2020-10-23 江苏为真生物医药技术股份有限公司 多肽、hla-dr蛋白及其制备方法和应用
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
WO2024044768A2 (en) * 2022-08-26 2024-02-29 The Board Of Trustees Of The Leland Stanford Junior University Chimeric cytokine receptors and methods of use
WO2025021112A1 (zh) * 2023-07-24 2025-01-30 佳吾益(北京)科技有限公司 开发mhc新抗原的工程化细胞
WO2025111562A1 (en) * 2023-11-22 2025-05-30 Cue Biopharma, Inc. Mhc class ii protein complexes

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0935607B1 (en) * 1996-08-16 2004-07-28 The President And Fellows Of Harvard College Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor
CA2328108A1 (en) 1998-05-07 1999-11-11 The Regents Of The University Of California Use of neglected target tissue antigens in modulation of immune responses
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
US20120083008A1 (en) * 2004-07-06 2012-04-05 Marshall Christopher P Methods for obtaining molecules with reduced immunogenicity
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US9267945B2 (en) 2008-11-12 2016-02-23 Yeda Research And Development Co. Ltd. Diagnosis of multiple sclerosis
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
WO2012121528A2 (en) * 2011-03-04 2012-09-13 Samsung Life Public Welfare Foundation Magnetic nanocomposite specific for thyroid cancer and use thereof
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
RU2015129640A (ru) * 2012-12-21 2017-01-26 Ф.Хоффманн-Ля Рош Аг Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
WO2015030842A1 (en) * 2013-08-31 2015-03-05 Halliburton Energy Services, Inc. Deflector assembly for a lateral wellbore
CN105899229A (zh) * 2013-11-04 2016-08-24 Uti有限合伙公司 用于持续的免疫治疗的方法和组合物
KR102825102B1 (ko) * 2014-12-24 2025-06-26 넥스이뮨, 인크. 면역요법을 위한 나노입자 조성물 및 방법
WO2016198932A2 (en) * 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy

Similar Documents

Publication Publication Date Title
JP2020500015A5 (cg-RX-API-DMAC7.html)
Miura et al. Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP7536294B2 (ja) 抗体のFc領域改変体
CN110382529B (zh) 工程化的异源二聚体蛋白质
JP2020506898A5 (cg-RX-API-DMAC7.html)
JP2021121642A (ja) 二特異性抗体基幹
KR101915740B1 (ko) 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질
JP2019150066A5 (cg-RX-API-DMAC7.html)
JP2024026255A5 (cg-RX-API-DMAC7.html)
JP2017522891A5 (cg-RX-API-DMAC7.html)
JP7356726B2 (ja) タンパク性ヘテロ二量体及びその使用
JP2014506790A5 (cg-RX-API-DMAC7.html)
KR20020026558A (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
JPWO2019234220A5 (cg-RX-API-DMAC7.html)
IL276286B1 (en) FC variants with improved binding to FCRN and extended half-life
JP2017501728A5 (cg-RX-API-DMAC7.html)
RU2015152077A (ru) Тримерные антигенсвязывающие молекулы
CN110713522B (zh) 低pH插入肽的胞外段作为抗原的应用
JP2014503198A5 (cg-RX-API-DMAC7.html)
JP2014510519A5 (cg-RX-API-DMAC7.html)
JP2020517260A5 (cg-RX-API-DMAC7.html)
CN115175920A (zh) 加条形码的xten多肽及其组合物以及其制备和使用方法
CN116964084A (zh) 双特异性抗体
JP2005523681A5 (cg-RX-API-DMAC7.html)